<- Go Home
ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Market Cap
EUR 9.2B
Volume
138.6K
Cash and Equivalents
EUR 477.4M
EBITDA
-EUR 254.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 4.9M
Profit Margin
100.00%
52 Week High
EUR 132.00
52 Week Low
EUR 6.35
Dividend
N/A
Price / Book Value
21.32
Price / Earnings
-25.53
Price / Tangible Book Value
22.64
Enterprise Value
EUR 8.7B
Enterprise Value / EBITDA
-34.59
Operating Income
-EUR 255.1M
Return on Equity
157.07%
Return on Assets
-44.65
Cash and Short Term Investments
EUR 491.6M
Debt
EUR 34.2M
Equity
EUR 429.6M
Revenue
EUR 4.9M
Unlevered FCF
-EUR 97.9M
Sector
Biotechnology
Category
N/A